Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Otlertuzumab - Aptevo Therapeutics

Next Previous
Drug Profile

Otlertuzumab - Aptevo Therapeutics

Alternative Names: TRU-016

Latest Information Update: 02 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Trubion Pharmaceuticals
  • Developer Aptevo Therapeutics
  • Class Antineoplastics; Monoclonal antibodies; Small molecules
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; CD37 protein inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma

Most Recent Events

  • 20 May 2021 Aptevo Therapeutics terminates a phase Ib trial for Chronic lymphocytic leukaemia (Combination therapy) and Peripheral T-cell lymphoma (Combination therapy, Second-line therapy or greater) in USA (IV), as per business decision (NCT01644253)
  • 14 Nov 2018 Discontinued - Phase-I for Chronic lymphocytic leukaemia (Combination therapy, First-line therapy) in USA (IV)
  • 14 Nov 2018 Discontinued - Phase-II for Chronic lymphocytic leukaemia (Combination therapy, Second-line therapy or greater) in Austria (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top